High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine

Timothy Wilkin; Jeannette Y. Lee; Shelly Y. Lensing; Elizabeth A. Stier; Stephen E. Goldstone; J. Michael Berry; Naomi Jay; David M. Aboulafia; Mark H. Einstein; Alfred Saah; Ronald T. Mitsuyasu; Joel M. Palefsky

doi:10.1310/hct1402-75

High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine

Timothy Wilkin, Jeannette Y. Lee, Shelly Y. Lensing, Elizabeth A. Stier, Stephen E. Goldstone, J. Michael Berry, Naomi Jay, David M. Aboulafia, Mark H. Einstein, Alfred Saah, Ronald T. Mitsuyasu, Joel M. Palefsky

Obstetrics & Gynecology and Women's Health

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Purpose: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. Methods: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. Results: HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P =.01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. Conclusion: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.

Original language	English (US)
Pages (from-to)	75-79
Number of pages	5
Journal	HIV Clinical Trials
Volume	14
Issue number	2
DOIs	https://doi.org/10.1310/hct1402-75
State	Published - Jan 1 2013

Keywords

HIV-1 infection
anal infection
anal intraepithelial neoplasia
human papillomavirus
male

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1310/hct1402-75

Cite this

Wilkin, T., Lee, J. Y., Lensing, S. Y., Stier, E. A., Goldstone, S. E., Berry, J. M., Jay, N., Aboulafia, D. M., Einstein, M. H., Saah, A., Mitsuyasu, R. T., & Palefsky, J. M. (2013). High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine. HIV Clinical Trials, 14(2), 75-79. https://doi.org/10.1310/hct1402-75

Wilkin, T, Lee, JY, Lensing, SY, Stier, EA, Goldstone, SE, Berry, JM, Jay, N, Aboulafia, DM, Einstein, MH, Saah, A, Mitsuyasu, RT & Palefsky, JM 2013, 'High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine', HIV Clinical Trials, vol. 14, no. 2, pp. 75-79. https://doi.org/10.1310/hct1402-75

@article{9bfed30ed5e241e1b71dd8d996a0a264,

title = "High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine",

abstract = "Purpose: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. Methods: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. Results: HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P =.01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. Conclusion: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.",

keywords = "HIV-1 infection, anal infection, anal intraepithelial neoplasia, human papillomavirus, male",

author = "Timothy Wilkin and Lee, {Jeannette Y.} and Lensing, {Shelly Y.} and Stier, {Elizabeth A.} and Goldstone, {Stephen E.} and Berry, {J. Michael} and Naomi Jay and Aboulafia, {David M.} and Einstein, {Mark H.} and Alfred Saah and Mitsuyasu, {Ronald T.} and Palefsky, {Joel M.}",

year = "2013",

month = jan,

day = "1",

doi = "10.1310/hct1402-75",

language = "English (US)",

volume = "14",

pages = "75--79",

journal = "HIV Clinical Trials",

issn = "1528-4336",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine

AU - Wilkin, Timothy

AU - Lee, Jeannette Y.

AU - Lensing, Shelly Y.

AU - Stier, Elizabeth A.

AU - Goldstone, Stephen E.

AU - Berry, J. Michael

AU - Jay, Naomi

AU - Aboulafia, David M.

AU - Einstein, Mark H.

AU - Saah, Alfred

AU - Mitsuyasu, Ronald T.

AU - Palefsky, Joel M.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Purpose: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. Methods: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. Results: HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P =.01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. Conclusion: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.

AB - Purpose: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. Methods: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. Results: HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P =.01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. Conclusion: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.

KW - HIV-1 infection

KW - anal infection

KW - anal intraepithelial neoplasia

KW - human papillomavirus

KW - male

UR - http://www.scopus.com/inward/record.url?scp=84878844175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878844175&partnerID=8YFLogxK

U2 - 10.1310/hct1402-75

DO - 10.1310/hct1402-75

M3 - Article

C2 - 23611828

AN - SCOPUS:84878844175

SN - 1528-4336

VL - 14

SP - 75

EP - 79

JO - HIV Clinical Trials

JF - HIV Clinical Trials

IS - 2

ER -

High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this